Intervention Review

You have full text access to this OnlineOpen article

Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples

  1. Andrew Anglemyer1,
  2. George W Rutherford1,*,
  3. Tara Horvath1,
  4. Rachel C Baggaley2,
  5. Matthias Egger3,
  6. Nandi Siegfried4,5

Editorial Group: Cochrane HIV/AIDS Group

Published Online: 30 APR 2013

Assessed as up-to-date: 26 FEB 2013

DOI: 10.1002/14651858.CD009153.pub3

How to Cite

Anglemyer A, Rutherford GW, Horvath T, Baggaley RC, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database of Systematic Reviews 2013, Issue 4. Art. No.: CD009153. DOI: 10.1002/14651858.CD009153.pub3.

Author Information

  1. 1

    University of California, San Francisco, Global Health Sciences, San Francisco, California, USA

  2. 2

    World Health Organization, Department of HIV/AIDS, Geneva, Switzerland

  3. 3

    Institute of Social and Preventive Medicine, Institute of Social Medicine, Bern, Switzerland

  4. 4

    University of Cape Town, Department of Psychiatry and Mental Health, Faculty of Health Sciences, Cape Town, South Africa

  5. 5

    University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, California, USA

*George W Rutherford, Global Health Sciences, University of California, San Francisco, San Francisco, California, 94105, USA. GRutherford@psg.ucsf.edu.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 30 APR 2013

SEARCH

[Figure 1]
Figure 1. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. Newcastle-Ottawa Scale for Bias Assessment
[Figure 3]
Figure 3. Screening process, PREVIOUS version of the review (Anglemyer 2011b)
[Figure 4]
Figure 4. Screening process, CURRENT version of the review.
[Figure 5]
Figure 5. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.1 Linked Incident HIV Infection.
[Figure 6]
Figure 6. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.2 All Incident HIV Infection.
[Figure 7]
Figure 7. Forest plot of comparison: 2 Treated with ART vs Not Treated with ART (Observational Studies), outcome: 2.1 Incident HIV Infection.
[Figure 8]
Figure 8. Forest plot of comparison: 3 Treated with ART vs Not Treated with ART (Observational Studies, sensitivity analysis), outcome: 3.1 Incident HIV Infection.
[Figure 9]
Figure 9. Forest plot of comparison: 3 Treated with ART vs Not Treated with ART (< 200, 200-350, and > 350 CD4 Subgroup Analysis) (Observational Studies), outcome: 3.1 Incident HIV Infection.
[Figure 10]
Figure 10. Forest plot of comparison: 5 Treated with ART vs Not Treated with ART (Female/Male Subgroup Analysis) (Observational Studies), outcome: 5.1 Incident HIV Infection.
[Figure 11]
Figure 11. Forest plot of comparison: 5 Treated with ART vs Not Treated with ART (Subgroup Analysis: LMIC) (Observational Studies), outcome: 5.1 Incident HIV Infection.
[Figure 12]
Figure 12. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.3 Severe or Life-Threatening Adverse Events (Grade 3 or 4).
[Figure 13]
Figure 13. Forest plot of comparison: 1 Delayed vs Immediate ART (RCTs), outcome: 1.4 Grade 3 or 4 Laboratory Abnormalities.
[Figure 14]
Figure 14. Funnel plot of comparison: 1 Treated with ART vs Not Treated with ART (Observational Studies), outcome: 2.1 Incident HIV Infection.
[Figure 15]
Figure 15. Funnel plot of comparison: 2 Treated with ART vs Not Treated with ART (Observational Studies, sensitivity analysis), outcome: 3.1 Incident HIV Infection.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 1 Linked Incident HIV Infection.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 2 All Incident HIV Infection.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 3 Severe or Life-Threatening Adverse Events (Grade 3 or 4).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Delayed vs Immediate ART (RCTs), Outcome 4 Grade 3 or 4 Laboratory Abnormalities.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Treated with ART vs Not Treated with ART (Observational Studies), Outcome 1 Incident HIV Infection.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Treated with ART vs Not Treated with ART (Observational Studies, sensitivity analysis), Outcome 1 Incident HIV Infection.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Treated with ART vs Not Treated with ART (< 200, 200-349, and ≥350 CD4 Cells/µL Subgroup Analysis) (Observational Studies), Outcome 1 Incident HIV Infection.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Treated with ART vs Not Treated with ART (Female/Male Subgroup Analysis) (Observational Studies), Outcome 1 Incident HIV Infection.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Treated with ART vs Not Treated with ART (Subgroup Analysis: Low-/Middle-Income vs High-income)) (Observational Studies), Outcome 1 Incident HIV Infection.